Dr. Devarakonda is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
Columbus, OH 43210Phone+1 614-293-3196Fax+1 614-293-4812
Summary
- I am a board certified hematologist and oncologist specialized in treating multiple myeloma, which is the second most common hematological malignancy after non-Hodgkin's lymphoma. I completed three years of Hematology/Oncology training in 2014 and have treated several patients with myeloma since then. My research interests include exploring the role of minimal residual disease in the management of multiple myeloma and incorporating it in the strategy towards cure for myeloma.
Education & Training
Louisiana State University School of MedicineFellowship, Hematology and Medical Oncology, 2011 - 2014
Robert Packer Hospital/GuthrieResidency, Internal Medicine, 2005 - 2008
Osmania Medical College NTR UHSClass of 2003
Certifications & Licensure
LA State Medical License 2009 - Present
OH State Medical License 2018 - 2025
PA State Medical License 2005 - 2018
MA State Medical License 2008 - 2011- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
- S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer Start of enrollment: 2011 Nov 25
- Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2013 Dec 06
- Join now to see all
Publications & Presentations
PubMed
- 96 citationsNCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, Larry D Anderson, Erica Campagnaro
Journal of the National Comprehensive Cancer Network. 2022-01-01 - 16 citationsMultiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson Jr, Muhamed Baljevic
Journal of the National Comprehensive Cancer Network. 2023-12-01 - 11 citationsAL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival.Michael Ozga, Qiuhong Zhao, Don M. Benson, Patrick Elder, Nita Williams
Cancer Medicine. 2021-02-01
Abstracts/Posters
- The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL AmyloidosisSrinivas Devarakonda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Improvement in Survival of Multiple Myeloma Patients: A Long-Term Institutional ExperienceSrinivas Devarakonda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell TransplantationSrinivas Devarakonda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Authored Content
- Longevity After Radiotherapy of Stage III Lung Cancer: Superior Vena Cava Obstruction Is Associated with Early MortalityApril 2018
Press Mentions
Navigating the Journey to Develop Safer CARsJuly 24th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
